Literature DB >> 15739042

Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage.

Jaume Roquer1, Ana Rodríguez Campello, Meritxell Gomis, Angel Ois, Victor Puente, Elvira Munteis.   

Abstract

BACKGROUND: Intracerebral hemorrhage (ICH) constitutes 10% to 15% of all strokes. Despite several existing outcome prediction models for ICH, there are some factors with equivocal value as well as others that still have not been evaluated. PATIENTS AND METHODS: All patients with first ever supratentorial ICH presenting to our institution between December 1995 and December 2002 were prospectively enrolled into the study. Patients with historic modified Rankin Scale > 2 and those under anticoagulant treatment or with multiple ICH were excluded. The following parameters were analyzed in 194 consecutive patients: age, gender, past history of hypertension, diabetes mellitus, hypercholesterolemia, past history of ischemic stroke, presence of ischemic heart disease or cardioembolic disease, current antiplatelet treatment, current alcohol overuse, smoking, Glasgow Coma Scale score (GSS) at admission, volume and location (deep or lobar) of ICH, ventricular extension, glycemia and temperature at admission, and leukoaraiosis. We correlated these data with the 30-day mortality identifying the independent predictors by logistic regression analysis.
RESULTS: Factors independently associated with 30-day mortality were: age, Glasgow Coma Scale score at admission, ICH volume, ventricular extension, glucose level at admission, and previous antiplatelet use.
CONCLUSIONS: Apart from the classical outcome predictors, the previous use of antiplatelet agents and the glucose value at admission are independent predictors of 30-day mortality in patients suffering a supratentorial ICH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15739042     DOI: 10.1007/s00415-005-0659-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Diabetes is an independent risk factor for in-hospital mortality from acute spontaneous intracerebral hemorrhage.

Authors:  A Arboix; J Massons; L García-Eroles; M Oliveres; C Targa
Journal:  Diabetes Care       Date:  2000-10       Impact factor: 19.112

2.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

3.  Spontaneous intracerebral hemorrhage. Prognostic factors in 896 cases.

Authors:  F Rosenow; C Hojer; C Meyer-Lohmann; R D Hilgers; H Mühlhofer; A Kleindienst; A Owega; W Köning; W D Heiss
Journal:  Acta Neurol Scand       Date:  1997-09       Impact factor: 3.209

4.  Intracranial hemorrhage and oral anticoagulant treatment.

Authors:  J P Neau; C Couderq; P Ingrand; P Blanchon; R Gil
Journal:  Cerebrovasc Dis       Date:  2001       Impact factor: 2.762

5.  Aspirin-associated intracerebral hemorrhage: clinical and radiologic features.

Authors:  K S Wong; V Mok; W W Lam; R Kay; A Tang; Y L Chan; J Woo
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

6.  Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage.

Authors:  J Berwaerts; R S Dijkhuizen; O J Robb; J Webster
Journal:  Stroke       Date:  2000-11       Impact factor: 7.914

7.  Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment.

Authors:  J A Rådberg; J E Olsson; C T Rådberg
Journal:  Stroke       Date:  1991-05       Impact factor: 7.914

8.  Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.

Authors:  Jordi Matías-Guiu; José M Ferro; José Alvarez-Sabín; Ferran Torres; M Dolores Jiménez; Aida Lago; Teresa Melo
Journal:  Stroke       Date:  2003-03-20       Impact factor: 7.914

9.  Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study.

Authors:  Søren P Johnsen; Lars Pedersen; Søren Friis; William J Blot; Joseph K McLaughlin; Jørgen H Olsen; Henrik T Sørensen
Journal:  Stroke       Date:  2003-02       Impact factor: 7.914

10.  Spontaneous supratentorial intracerebral hemorrhage. Criteria for short-term functional outcome prediction.

Authors:  Chen Hallevy; Gal Ifergane; Ella Kordysh; Yuval Herishanu
Journal:  J Neurol       Date:  2002-12       Impact factor: 4.849

View more
  30 in total

1.  The slippery slope of platelet transfusion for intracerebral hemorrhage.

Authors:  Wendy C Ziai; Marek A Mirski
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

2.  Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage.

Authors:  Andrew M Naidech; Storm M Liebling; Neil F Rosenberg; Paul F Lindholm; Richard A Bernstein; H Hunt Batjer; Mark J Alberts; Hau C Kwaan
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

3.  Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage.

Authors:  Michael Moussouttas
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

4.  Is platelet activity important in acute intracerebral hemorrhage?

Authors:  Christine A C Wijman
Journal:  Neurocrit Care       Date:  2009-08-28       Impact factor: 3.210

5.  Prior Antiplatelet Therapy, Excluding Phosphodiesterase Inhibitor Is Associated with Poor Outcome in Patients with Spontaneous Intracerebral Haemorrhage.

Authors:  Zhuo-Hao Liu; Chi-Hung Liu; Po-Hsun Tu; Ping K Yip; Ching-Chang Chen; Yu-Chi Wang; Nan-Yu Chen; Yu-Sheng Lin
Journal:  Transl Stroke Res       Date:  2019-08-24       Impact factor: 6.829

6.  Predictors of 30-day mortality and 90-day functional recovery after primary intracerebral hemorrhage : hospital based multivariate analysis in 585 patients.

Authors:  Kyu-Hong Kim
Journal:  J Korean Neurosurg Soc       Date:  2009-06-30

7.  Warfarin use leads to larger intracerebral hematomas.

Authors:  M L Flaherty; H Tao; M Haverbusch; P Sekar; D Kleindorfer; B Kissela; P Khatri; B Stettler; O Adeoye; C J Moomaw; J P Broderick; D Woo
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

8.  PATCH: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial.

Authors:  Koen de Gans; Rob J de Haan; Charles B Majoie; Maria M Koopman; Anneke Brand; Marcel G Dijkgraaf; Marinus Vermeulen; Yvo B Roos
Journal:  BMC Neurol       Date:  2010-03-18       Impact factor: 2.474

9.  Effect of aspirin and warfarin on early survival after intracerebral haemorrhage.

Authors:  H Carl Hanger; Valerie J Fletcher; Tim J Wilkinson; Allan J Brown; Chris M Frampton; Richard Sainsbury
Journal:  J Neurol       Date:  2008-02-26       Impact factor: 4.849

10.  Reduced platelet activity is more common than reported anti-platelet medication use in patients with intracerebral hemorrhage.

Authors:  Andrew M Naidech; Sarice L Bassin; Richard A Bernstein; H Hunt Batjer; Mark J Alberts; Paul F Lindholm; Thomas P Bleck
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.